NVO

Novo Nordisk (NVO) closed down 1.06% and has depreciated 10.2% over the past month, underperforming the broader market. The company faces headwinds with projected EPS declining 20.59% for the upcoming quarter and full-year earnings expected to drop 13.64% year-over-year. The stock carries a Zacks Rank #3 (Hold) rating, though it trades at a discount to its industry peers with a Forward P/E of 11.36 versus the industry average of 16.91.

Novo Nordisk (NVO) has underperformed the broader market, declining 10.2% over the past month compared to the S&P 500's 1.5% gain. The company faces earnings headwinds with expected EPS declining 20.6% year-over-year for the current quarter and 13.6% for the fiscal year. However, the stock trades at a valuation discount to peers and maintains a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Novo Nordisk (NVO) closed down 1.35% and has fallen 11.21% over the past month, underperforming the S&P 500. The company is expected to report a 20.59% year-over-year earnings decline with revenue down 3.03%. The stock holds a Zacks Rank of #3 (Hold) with a Forward P/E of 11.29, trading at a discount to its industry average, though analyst consensus estimates have moved 3.17% lower in the past month.